PROSTACOX : Metastatic Prostate Chemotherapy

This study has been completed.

First Received: September 13, 2005 Last Updated: September 25, 2006 History of Changes

Sponsored by:	University Hospital, Rouen
Information provided by:	University Hospital, Rouen
ClinicalTrials.gov Identifier:	NCT00213694

Purpose

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Condition	Intervention	Phase
Metastatic Prostate Cancer	Drug: docetaxel and celecoxib	Phase II

MedlinePlus related topics: Cancer Prostate Cancer

Drug Information available for: Docetaxel Celecoxib

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Longitudinal, Defined Population, Prospective Study
Official Title:	Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Further study details as provided by University Hospital, Rouen:

Estimated Enrollment:	52
Study Start Date:	November 2003
Estimated Study Completion Date:	June 2006

Detailed Description:

Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

metastatic prostate cancer
ASCO progression criteria

Exclusion Criteria:

other prostate chemotherapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213694

Locations

France
Charles Nicolle, University Hospital
ROUEN, France, 76031

Sponsors and Collaborators

University Hospital, Rouen

Investigators

Principal Investigator:

Christian PFISTER, MD, PhD

University Hospital, Rouen

More Information

No publications provided

Study ID Numbers:	2003/052 HP
Study First Received:	September 13, 2005
Last Updated:	September 25, 2006
ClinicalTrials.gov Identifier:	NCT00213694 History of Changes
Health Authority:	France: Afssaps - French Health Products Safety Agency

Study placed in the following topic categories:

Anti-Inflammatory Agents
Celecoxib
Genital Neoplasms, Male
Prostatic Diseases
Cyclooxygenase Inhibitors
Urogenital Neoplasms
Genital Diseases, Male

Docetaxel
Analgesics, Non-Narcotic
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Prostatic Neoplasms

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Celecoxib
Molecular Mechanisms of Pharmacological Action
Genital Neoplasms, Male
Prostatic Diseases
Antineoplastic Agents
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Urogenital Neoplasms
Genital Diseases, Male
Pharmacologic Actions

Docetaxel
Neoplasms
Neoplasms by Site
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Peripheral Nervous System Agents
Analgesics
Antirheumatic Agents
Central Nervous System Agents
Prostatic Neoplasms

ClinicalTrials.gov processed this record on May 07, 2009